Live Breaking News & Updates on Pura Vida Investments Llc

Stay updated with breaking news from Pura vida investments llc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a research report released on Monday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC lowered their price target on shares of OncoCyte from $1.40 to $0.45 and set a buy rating on the stock in a […] ....

Pura Vida Investments Llc , Oncocyte Company Profile , Balyasny Asset Management , Cubist Systematic Strategies , Needham Company , Oncocyte Corp , Raymond James Financial Services Advisors Inc , Get Rating , Pura Vida Investments , Broadwood Partners , James Financial Services Advisors , Systematic Strategies , Asset Management , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a report published on Monday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC cut their price target on shares of OncoCyte from $1.40 to $0.45 and set a buy rating on the stock in a report […] ....

Oncocyte Company Profile , Needham Company , Pura Vida Investments Llc , Defender Capital , Millennium Management , Goldman Sachs Group Inc , Vanguard Group Inc , Oncocyte Corp , Get Rating , Cyte Stock Down , Pura Vida Investments , Broadwood Partners , Sachs Group , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a research note published on Saturday. The firm issued a sell rating on the stock. Separately, Needham & Company LLC lowered their price target on OncoCyte from $1.40 to $0.45 and set a buy rating on the stock in a report on Tuesday, […] ....

United Kingdom , Cubist Systematic Strategies , Millennium Management , Goldman Sachs Group Inc , Defender Capital , Oncocyte Company Profile , Pura Vida Investments Llc , Balyasny Asset Management , Securities Exchange Commission , Oncocyte Corp , Needham Company , Get Rating , Pura Vida Investments , Exchange Commission , Broadwood Partners , Asset Management , Sachs Group , Systematic Strategies , Oncocyte Daily ,

OncoCyte (NASDAQ:OCX) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a research note released on Thursday. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC decreased their price target on OncoCyte from $1.40 to $0.45 and set a buy rating for the company in a research note on […] ....

Cubist Systematic Strategies , Pura Vida Investments Llc , Securities Exchange Commission , Needham Company , Oncocyte Corp , Raymond James Financial Services Advisors Inc , Balyasny Asset Management , Get Rating , Pura Vida Investments , Broadwood Partners , Exchange Commission , Systematic Strategies , James Financial Services Advisors , Asset Management , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Get Rating) in a report issued on Friday. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC cut their target price on shares of OncoCyte from $1.40 to $0.45 and set a buy rating on the stock in a research report […] ....

Balyasny Asset Management , Securities Exchange Commission , Cubist Systematic Strategies , Oncocyte Corp , Needham Company , Raymond James Financial Services Advisors Inc , Pura Vida Investments Llc , Get Rating , Pura Vida Investments , Exchange Commission , Broadwood Partners , Systematic Strategies , James Financial Services Advisors , Asset Management , Oncocyte Daily ,